Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year
Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively
Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales
Company Estimates 2026 Net Sales in a Range of $340-360 Million
Announces $100 Million Share Repurchase Program Authorization
Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET
MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2025.
Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "MIMEDX delivered a record year of revenue and profitability in 2025, with fourth quarter results that included net sales growth of 27% year-over-year, net income of $15 million, an Adjusted EBITDA margin of 25% of net sales, and robust free cash flow. These results were driven by strong double-digit contributions in both Wound and Surgical, which grew 28% and 25%, respectively, reflecting exceptional commercial execution across the markets we serve. We were particularly pleased with the durable double-digit growth seen in Surgical, and we are keenly focused on the untapped clinical opportunities for our current and future products."
Mr. Capper continued, "Looking ahead to 2026, the Company remains committed to providing a best-in-class portfolio of evidence-based, differentiated products to capitalize on the many opportunities in front of us. With the recent product additions to our Wound and Surgical offerings, I am as confident as ever in our ability to make significant headway this year in a variety of clinical settings."
"The short-term disruptions caused by Medicare reimbursement changes in the Wound market will likely have an impact on our 2026 revenue. Once demand patterns normalize, we expect to gain significant volume over time. Meanwhile, we believe the clear momentum we have across the rest of our business — Surgical, international and Wound commercial pay — will provide continued profitability and cash flow. Thus, enabling us to maintain our leadership position over both the short- and long-term," concluded Mr. Capper.
____________________
1 Adjusted EBITDA is a Non-GAAP Measure. This press release contains this and other Non-GAAP measures. For reconciliations of our Non-GAAP measures to their nearest GAAP measure, refer to the section titled "Reconciliation of Non-GAAP Measures" below.
Fourth Quarter and Full Year 2025 Results Discussion
Net Sales
MIMEDX reported net sales for the three months ended December 31, 2025 of $118 million, compared to $93 million for the three months ended December 31, 2024, an increase of 27%. The increase was driven by Wound product sales growth of 28%, which reflected the introduction of EPIXPRESS® as well as the contribution from EMERGE™ during the quarter. Additionally, fourth quarter Surgical sales grew 25% and represented the sixth consecutive quarter of sequential sales growth for this product category, led by sustained momentum for AMNIOFIX® and AMNIOEFFECT® as well as another strong performance for the Company's particulate portfolio.
For the full year 2025 MIMEDX reported net sales of $419 million, compared to $349 million in the prior year period, reflecting growth of 20%. On a full year basis, Wound growth of 20% was led by sales of new products, including CELERA™, EMERGE, and EPIXPRESS, which more than offset pressure from lower-priced products. Also in 2025, Surgical net sales rose 21% compared to the prior year period, with strong contributions from AMNIOFIX, AMNIOEFFECT and HELIOGEN®.
Gross Profit and Margin
Gross profit for the three months ended December 31, 2025, was $99 million, an increase of $23 million as compared to the prior year period. Gross margin for the three months ended December 31, 2025 was 84%, compared to 82% in the prior year period. The increase was driven by favorable product mix. On an adjusted basis, fourth quarter 2025 gross margin was 86%, which reflects a roughly flat adjusted gross margin compared to the prior year period.
For the full year 2025, gross profit was $346 million, reflecting an increase of $57 million compared to the prior year period. Additionally, gross margin for the full year 2025 was 83%, flat compared to the full year 2024. On an adjusted basis, gross margin for the full year 2025 was 86% compared to 84% for the full year 2024.
Operating Expenses
Selling, general and administrative ("SG&A") expenses for the three months ended December 31, 2025, were $73 million compared to $61 million for the three months ended December 31, 2024. For the full year 2025, SG&A expenses totaled $266 million, compared to $225 million for the prior period, reflecting a year over year increase of 18%. For both the fourth quarter and full year 2025, the year-over-year increase in SG&A was driven primarily by higher commissions.
Research and development ("R&D") expenses for the three months ended December 31, 2025, were $5 million compared to $4 million for the three months ended December 31, 2024. For the full year 2025, research and development expenses totaled $15 million, compared to $12 million for 2024. R&D spend in the quarter and year was driven, in part, by the randomized controlled trial for EPIEFFECT and ongoing investments in the development of future products in our pipeline.
Net income for the three months and full year ended December 31, 2025 was $15 million and $49 million, respectively, compared to a net income of $7 million and $42 million for the three months and full year ended December 31, 2024, respectively.
Cash and Cash Equivalents
As of December 31, 2025, the Company had $166 million of cash and cash equivalents compared to $104 million as of December 31, 2024 and $142 million as of September 30, 2025. As of December 31, 2025, our cash position, net of debt on our balance sheet, was $148 million, representing a sequential increase of $24 million and an increase of $63 million for the year.
Share Repurchase Authorization Announced
Also today, the MIMEDX Board of Directors has authorized a share repurchase program of up to $100 million of the Company’s common stock over a two-year period. The share repurchase program provides MIMEDX with the flexibility to purchase shares of its common stock in the open market or in privately negotiated transactions, subject to market conditions and other factors.
MIMEDX intends to use the repurchase program periodically on a discretionary basis, subject to general business and market conditions and balanced against other investment opportunities. The repurchase program may be commenced, suspended or discontinued at any time.
MIMEDX remains focused on executing its strategic priorities and its decision to establish this repurchase program reflects its balanced approach to capital allocation.
Financial Outlook
For 2026, MIMEDX currently estimates net sales to be in a range of $340 to $360 million and for adjusted EBITDA margin to be in the mid-to-high teens.
Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%.
Conference Call and Webcast
MIMEDX will host a conference call and webcast to review its fourth quarter and full year 2025 results on Wednesday, February 25, 2026, beginning at 4:30 p.m., Eastern Time. The call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13758446
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
Important Cautionary Statement
This press release and our investor conference call include forward-looking statements, which reflect management's current beliefs and expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties. These statements include statements regarding: (i) future sales, sales growth, and Adjusted EBITDA margin; (ii) our longer term financial goals and expectations for future financial results, including levels of net sales, Adjusted EBITDA, and Adjusted EBITDA margin; (iii) our expectations regarding the size of the market for our products;(iv) our expectations regarding the impact of CMS' updated 2026 Medicare reimbursement rules and model and our belief that Medicare is likely to introduce national coverage policy, given the withdrawal of the LCDs; (v) continued growth in different care settings and different products, specifically accounting for the change caused by CMS' updated 2026 reimbursement rules and model; and (vi) our expected outcomes relating to improving workflow and strengthening bonds between the Company and its customers. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.
Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment, particularly in light of CMS' updated 2026 Medicare spending rules and reimbursement model, and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; (vi) we may alter the timing and amount of planned expenditures for research and development based on regulatory developments; (vii) the impact of CMS' updated 2026 spending rules and reimbursement model, particularly the shift to a capped rate for Medicare reimbursement, including the impact on our product utilization given the potential shift to alternate treatment modalities; and (viii) changes in the size of the addressable market for our products. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470.304.7291
mnotarianni@mimedx.com
Selected Unaudited Financial Information
| MiMedx Group, Inc. | |||||||
| Condensed Consolidated Balance Sheets | |||||||
| (in thousands) Unaudited | |||||||
| December 31, | |||||||
| 2025 | 2024 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 166,121 | $ | 104,416 | |||
| Accounts receivable, net | 75,707 | 55,828 | |||||
| Inventory | 25,340 | 23,807 | |||||
| Other current assets | 10,303 | 7,835 | |||||
| Total current assets | 277,471 | 191,886 | |||||
| Property and equipment, net | 4,713 | 5,944 | |||||
| Deferred tax assets | 19,596 | 28,306 | |||||
| Goodwill | 19,441 | 19,441 | |||||
| Intangible assets, net | 14,158 | 11,626 | |||||
| Other assets | 7,274 | 6,712 | |||||
| Total assets | $ | 342,653 | $ | 263,915 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Current portion of long term debt | $ | 1,500 | $ | 1,000 | |||
| Accounts payable | 14,528 | 7,409 | |||||
| Accrued compensation | 31,065 | 23,667 | |||||
| Accrued expenses | 11,383 | 9,012 | |||||
| Other current liabilities | 5,790 | 4,507 | |||||
| Total current liabilities | 64,266 | 45,595 | |||||
| Long term debt, net | 16,467 | 17,830 | |||||
| Other liabilities | 5,372 | 7,383 | |||||
| Total liabilities | $ | 86,105 | $ | 70,808 | |||
| Stockholders’ equity | |||||||
| Common stock; $.001 par value; 250,000,000 shares authorized, 148,093,920 issued and outstanding at December 31, 2025 and 146,932,032 issued and outstanding at December 31, 2024 | 148 | 147 | |||||
| Additional paid-in capital | 299,081 | 284,219 | |||||
| Accumulated deficit | (42,681 | ) | (91,259 | ) | |||
| Total stockholders’ equity | 256,548 | 193,107 | |||||
| Total liabilities and stockholders’ equity | $ | 342,653 | $ | 263,915 | |||
| MiMedx Group, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||||
| (in thousands, except share and per share amounts) Unaudited | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net sales | $ | 118,095 | $ | 92,907 | $ | 418,630 | $ | 348,879 | |||||||
| Cost of sales | 19,055 | 16,909 | 73,013 | 60,073 | |||||||||||
| Gross profit | 99,040 | 75,998 | 345,617 | 288,806 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 73,073 | 61,043 | 266,194 | 225,087 | |||||||||||
| Research and development | 4,761 | 3,571 | 15,097 | 12,341 | |||||||||||
| Investigation, restatement and related | — | 43 | — | (8,698 | ) | ||||||||||
| Amortization of intangible assets | 128 | 194 | 439 | 765 | |||||||||||
| Impairment of intangible assets | — | 94 | — | 446 | |||||||||||
| Operating income | 21,078 | 11,053 | 63,887 | 58,865 | |||||||||||
| Other income (expense), net | |||||||||||||||
| Interest income (expense), net | 904 | 403 | 2,933 | (1,006 | ) | ||||||||||
| Other expense, net | (186 | ) | (208 | ) | (558 | ) | (565 | ) | |||||||
| Income from continuing operations before income tax | 21,796 | 11,248 | 66,262 | 57,294 | |||||||||||
| Income tax provision (expense) benefit from continuing operations | (6,605 | ) | (3,811 | ) | (17,684 | ) | (15,296 | ) | |||||||
| Net income from continuing operations | 15,191 | 7,437 | 48,578 | 41,998 | |||||||||||
| Income (loss) from discontinued operations, net of tax | — | — | — | 421 | |||||||||||
| Net income | $ | 15,191 | $ | 7,437 | $ | 48,578 | $ | 42,419 | |||||||
| Net income available to common stockholders from continuing operations | $ | 15,191 | $ | 7,437 | $ | 48,578 | $ | 41,998 | |||||||
| Basic net income (loss) per common share: | |||||||||||||||
| Continuing operations | $ | 0.10 | $ | 0.05 | $ | 0.33 | $ | 0.29 | |||||||
| Discontinued operations | — | — | — | — | |||||||||||
| Basic net income per common share: | $ | 0.10 | $ | 0.05 | $ | 0.33 | $ | 0.29 | |||||||
| Diluted net income (loss) per common share: | |||||||||||||||
| Continuing operations | $ | 0.10 | $ | 0.05 | $ | 0.32 | $ | 0.28 | |||||||
| Discontinued operations | — | — | — | — | |||||||||||
| Diluted net income (loss) per common share: | $ | 0.10 | $ | 0.05 | $ | 0.32 | $ | 0.28 | |||||||
| Weighted average common shares outstanding - basic | 148,091,670 | 147,008,235 | 147,793,069 | 146,979,354 | |||||||||||
| Weighted average common shares outstanding - diluted | 150,189,160 | 149,242,415 | 149,724,507 | 149,049,197 | |||||||||||
| MiMedx Group, Inc. | |||||||||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||||||||
| (in thousands) Unaudited | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net cash flows provided by operating activities | $ | 24,956 | $ | 18,782 | $ | 74,003 | $ | 66,198 | |||||||
| Net cash flows used in investing activities | (335 | ) | (2,767 | ) | (6,886 | ) | (9,583 | ) | |||||||
| Net cash flows used in financing activities | (583 | ) | (400 | ) | (5,412 | ) | (34,199 | ) | |||||||
| Net change in cash | $ | 24,038 | $ | 15,615 | $ | 61,705 | $ | 22,416 | |||||||
Reconciliation of Non-GAAP Measures
In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted Net Income. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measures are not a substitute for GAAP measures. Company management uses these non-GAAP measures as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies.
These non-GAAP financial measures reflect the exclusion of the following items:
- Share-based compensation expense - expense recognized related to awards to employees and our board of directors pursuant to our share-based compensation plans. This expense is reflected amongst cost of sales, research and development expense, and selling, general, and administrative expense in the consolidated statements of operations.
- Investigation, restatement, and related (benefit) expense - expenses incurred toward the legal defense of the Company and advanced on behalf of certain former officers and directors, net of negotiated reductions and settlements of amounts previously advanced, related to certain legal matters. This expense is reflected in the line of the same name in our consolidated statements of operations.
- Impairment of intangible assets - reflects the impairment of intangibles. This expense is reflected in the line of the same name in our consolidated statements of operations.
- Transaction-related expenses - reflects expenses incrementally incurred resulting from the consummation of material strategic transactions or the integration of acquired assets or operations into our core business.
- Strategic legal and regulatory expenses - With respect to the three months and year ended December 31, 2025, this relates to litigation and regulatory expenses. Litigation expenses incurred relate to suits filed against former employees and their employers for violation of non-compete and non-solicitation agreements and related matters. Regulatory expenses relate to legal fees incurred stemming from action taken against the United States Food & Drug Administration ("FDA") surrounding the designation of one of our products.
- Loss on extinguishment of debt - reflects the excess of cash paid to extinguish debt over the carrying value of the debt on our balance sheet upon the repayment and termination of a loan agreement. With respect to the year ended December 31, 2025, this relates to the repayment and termination of the Company's loan agreement with Hayfin. Amounts in this line reflect (i) prepayment premium paid and (ii) write-offs of unamortized original issue discount and deferred financing costs.
- Expenses related to the Disbanding of Regenerative Medicine - incremental expenses recognized or incurred directly as a result of our announcement to disband our Regenerative Medicine segment.
- Amortization of acquired intangible assets - reflects amortization expense recognized solely related to assets which were acquired as part of a transaction. These expenses are reflected in cost of sales in our consolidated statements of operations.
- Reorganization expenses - reflects severance expense arising from the enactment of various strategic initiatives, including separations from certain officers of the Company.
- Income Tax Adjustment - for purposes of calculating Adjusted Net Income and Adjusted Earnings Per Share, reflects our expectation of a long-term effective tax rate, which is normalized and balance sheet-agnostic. Actual reporting tax expense will be based on GAAP earnings, and may differ from the expected long-term effective tax rate due to a variety of factors, including the tax treatment of various transactions included in GAAP net income and other reconciling items that are excluded in determining Adjusted Net Income and Adjusted EPS. The actual long-term normalized effective tax rate was 25% for each of the years ended December 31, 2025 and 2024.
Adjusted EBITDA and Adjusted EBITDA margin
Adjusted EBITDA consists of GAAP net income excluding: (i) share-based compensation, (ii) income tax provision, (iii) amortization of intangible assets, (iv) strategic legal and regulatory expenses, (v) interest (income) expense, net, (vi) depreciation expense, (vii) reorganization expenses, (viii) transaction-related expenses, (ix) investigation, restatement and related expense (benefit), (x) impairment of intangible assets, and (xi) expenses related to disbanding of the Regenerative Medicine business unit.
A reconciliation of GAAP net income to Adjusted EBITDA appears in the table below (dollars in thousands):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net Income | $ | 15,191 | $ | 7,437 | $ | 48,578 | $ | 42,419 | |||||||
| Non-GAAP Adjustments: | |||||||||||||||
| Share-based compensation | 2,463 | 4,693 | 16,396 | 16,933 | |||||||||||
| Income tax provision | 6,605 | 3,811 | 17,684 | 15,296 | |||||||||||
| Amortization of intangible assets | 2,648 | 2,426 | 12,617 | 3,762 | |||||||||||
| Strategic legal and regulatory expenses | 2,494 | 1,140 | 9,185 | 2,806 | |||||||||||
| Interest (income) expense, net | (904 | ) | (403 | ) | (2,933 | ) | 1,006 | ||||||||
| Depreciation expense | 572 | 564 | 2,264 | 2,279 | |||||||||||
| Reorganization expense | 203 | — | 1,029 | — | |||||||||||
| Transaction related expenses | 103 | (38 | ) | 902 | 612 | ||||||||||
| Investigation, restatement and related expenses | — | 44 | — | (8,698 | ) | ||||||||||
| Impairment of intangible assets | — | 94 | — | 446 | |||||||||||
| Expenses related to disbanding of Regenerative Medicine business unit | — | — | — | (421 | ) | ||||||||||
| Adjusted EBITDA | $ | 29,375 | $ | 19,768 | $ | 105,722 | $ | 76,440 | |||||||
| Adjusted EBITDA margin | 24.9 | % | 21.3 | % | 25.3 | % | 21.9 | % | |||||||
Adjusted Net Income and Adjusted Gross Margin
Adjusted Net Income provides a view of our operating performance, exclusive of certain items which are non-recurring or not reflective of our core operations.
Adjusted Net Income is defined as GAAP net income plus (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) transaction-related expenses, (iv) reorganization expenses, (v) investigation, restatement and related expense (benefit), (vi) impairment of intangible assets, (vii) loss on extinguishment of debt, (viii) expenses related to disbanding of Regenerative Medicine business unit, and (ix) the long-term effective income tax rate adjustment.
Each of the adjustments to reconcile Adjusted Net Income to GAAP net income affect individual financial statement captions which are reflected in our consolidated statements of operations, including gross profit. Adjusted Gross Profit is therefore defined as GAAP gross profit plus (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) transaction-related expenses, (iv) reorganization expenses, (v) investigation, restatement and related expense (benefit), (vi) impairment of intangible assets, (vii) loss on extinguishment of debt, (viii) expenses related to disbanding of Regenerative Medicine business unit, and (ix) the long-term effective income tax rate adjustment
to the extent that these adjustments impact GAAP gross profit. Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by GAAP net sales.
A reconciliation of GAAP net income to Adjusted Net Income appears in the table below (in thousands):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net income | $ | 15,191 | $ | 7,437 | $ | 48,578 | $ | 42,419 | |||||||
| Amortization of acquired intangible assets | 2,519 | 2,232 | 12,178 | 2,997 | |||||||||||
| Strategic legal and regulatory expenses | 2,494 | 1,140 | 9,185 | 2,806 | |||||||||||
| Transaction related expenses | 103 | (38 | ) | 902 | 612 | ||||||||||
| Reorganization expense | 203 | — | 1,029 | — | |||||||||||
| Investigation, restatement and related expense (benefit) | — | 43 | — | (8,698 | ) | ||||||||||
| Impairment of intangible assets | — | 94 | — | 446 | |||||||||||
| Loss on extinguishment of debt | — | — | — | 1,401 | |||||||||||
| Expenses related to disbanding of Regenerative Medicine business unit | — | — | — | (421 | ) | ||||||||||
| Long-term effective income tax rate adjustment | (174 | ) | 130 | (4,705 | ) | 1,082 | |||||||||
| Adjusted net income | $ | 20,336 | $ | 11,038 | $ | 67,167 | $ | 42,644 | |||||||
A reconciliation of various line items included in our GAAP unaudited condensed consolidated statements of operations to Adjusted Net Income, including Adjusted Gross Profit for the three months and years ended December 31, 2025 and 2024 are presented in the tables below (in thousands):
| Three months ended December 31, 2025 | ||||||||||||||
| Gross Profit | Selling, General & Administrative Expense | Research and Development Expense | Net Income | |||||||||||
| Reported GAAP Measure | $ | 99,040 | $ | 73,073 | $ | 4,761 | $ | 15,191 | ||||||
| Amortization of acquired intangible assets | 2,519 | — | — | 2,519 | ||||||||||
| Strategic legal and regulatory expenses | — | (2,494 | ) | — | 2,494 | |||||||||
| Reorganization expense | (203 | ) | 203 | |||||||||||
| Transaction-related expenses | — | (90 | ) | — | 103 | |||||||||
| Long-term effective income tax rate adjustment | — | — | — | (174 | ) | |||||||||
| Non-GAAP Measure | $ | 101,559 | $ | 70,286 | $ | 4,761 | $ | 20,336 | ||||||
| Reported Gross Profit Margin | 83.9 | % | ||||||||||||
| Adjusted Gross Profit Margin | 86.0 | % | ||||||||||||
| Three months ended December 31, 2024 | ||||||||||||||
| Gross Profit | Selling, General & Administrative Expense | Research and Development Expense | Net Income | |||||||||||
| Reported GAAP Measure | $ | 75,998 | $ | 61,043 | $ | 3,571 | $ | 7,437 | ||||||
| Investigation, restatement and related expenses | — | — | — | 43 | ||||||||||
| Impairment of intangible assets | — | — | — | 94 | ||||||||||
| Amortization of acquired intangible assets | 2,232 | — | — | 2,232 | ||||||||||
| Transaction-related expenses | — | (30 | ) | — | (38 | ) | ||||||||
| Strategic legal and regulatory expenses | — | (1,140 | ) | — | 1,140 | |||||||||
| Long-term effective income tax rate adjustment | — | — | — | 130 | ||||||||||
| Non-GAAP Measure | $ | 78,230 | $ | 59,873 | $ | 3,571 | $ | 11,038 | ||||||
| Reported Gross Profit Margin | 81.8 | % | ||||||||||||
| Adjusted Gross Profit Margin | 84.2 | % | ||||||||||||
| Year Ended December 31, 2025 | ||||||||||||||
| Gross Profit | Selling, General & Administrative Expense | Research and Development Expense | Net Income | |||||||||||
| Reported GAAP Measure | $ | 345,617 | $ | 266,194 | $ | 15,097 | $ | 48,578 | ||||||
| Amortization of acquired intangible assets | 12,178 | — | — | 12,178 | ||||||||||
| Strategic legal and regulatory expenses | — | (9,185 | ) | — | 9,185 | |||||||||
| Transaction-related expenses | — | (779 | ) | — | 902 | |||||||||
| Reorganization expense | — | (1,029 | ) | — | 1,029 | |||||||||
| Long-term effective income tax rate adjustment | — | — | — | (4,705 | ) | |||||||||
| Non-GAAP Measure | $ | 357,795 | $ | 255,201 | $ | 15,097 | $ | 67,167 | ||||||
| Reported Gross Profit Margin | 82.6 | % | ||||||||||||
| Adjusted Gross Profit Margin | 85.5 | % | ||||||||||||
| Year Ended December 31, 2024 | ||||||||||||||
| Gross Profit | Selling, General & Administrative Expense | Research and Development Expense | Net Income | |||||||||||
| Reported GAAP Measure | $ | 288,806 | $ | 225,087 | $ | 12,341 | 42,419 | |||||||
| Loss on extinguishment of debt | — | — | — | 1,401 | ||||||||||
| Investigation, restatement and related expenses | — | — | — | (8,698 | ) | |||||||||
| Impairment of intangible assets | — | — | — | 446 | ||||||||||
| Amortization of acquired intangible assets | 2,997 | — | — | 2,997 | ||||||||||
| Transaction-related expenses | — | (551 | ) | — | 612 | |||||||||
| Strategic legal and regulatory expenses | — | (2,806 | ) | — | 2,806 | |||||||||
| Expenses related to disbanding of Regenerative Medicine Business Unit | — | — | — | (421 | ) | |||||||||
| Long-term effective income tax rate adjustment | — | — | — | 1,082 | ||||||||||
| Non-GAAP Measure | $ | 291,803 | $ | 221,730 | $ | 12,341 | $ | 42,644 | ||||||
| Reported Gross Profit Margin | 82.8 | % | ||||||||||||
| Adjusted Gross Profit Margin | 83.6 | % | ||||||||||||
Adjusted Earnings Per Share
Adjusted Earnings Per Share is intended to provide a normalized view of earnings per share by removing items that may be irregular, one-time, or non-recurring from net income. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted Earnings Per Share consists of GAAP diluted net income per common share including adjustments for: (i) amortization of acquired intangible assets, (ii) strategic legal and regulatory expenses, (iii) transaction-related expenses, (iv) reorganization expenses, (v) investigation, restatement and related expense (benefit), (vi) impairment of intangible assets, (vii) loss on extinguishment of debt, (viii) expenses related to disbanding of Regenerative Medicine business unit, and (ix) the long-term effective income tax rate adjustment. The effect of antidilution reflects the changes resulting from the removal of the dilutive impact of convertible securities which were dilutive for purposes of calculating GAAP net income per common share, but are antidilutive for non-GAAP purposes.
A reconciliation of GAAP diluted earnings per share to Adjusted Earnings Per Share appears in the table below (per diluted share):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||
| GAAP net income (loss) per common share - diluted | $ | 0.10 | $ | 0.05 | $ | 0.32 | $ | 0.28 | |||||
| Loss on extinguishment of debt | 0.00 | 0.00 | 0.00 | 0.01 | |||||||||
| Investigation, restatement and related (benefit) expense | 0.00 | 0.00 | 0.00 | (0.06 | ) | ||||||||
| Impairment of intangible assets | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Amortization of acquired intangible assets | 0.02 | 0.01 | 0.08 | 0.02 | |||||||||
| Transaction related expenses | 0.00 | 0.00 | 0.01 | 0.00 | |||||||||
| Strategic legal and regulatory expenses | 0.02 | 0.01 | 0.06 | 0.02 | |||||||||
| Expenses related to disbanding of Regenerative Medicine business unit | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||
| Reorganization expenses | 0.00 | 0.00 | 0.01 | 0.00 | |||||||||
| Long-term effective income tax rate adjustment | 0.00 | 0.00 | (0.03 | ) | 0.01 | ||||||||
| Adjusted Earnings Per Share | $ | 0.14 | $ | 0.07 | $ | 0.45 | $ | 0.28 | |||||
| Weighted average common shares outstanding - adjusted | 150,189,160 | 149,242,415 | 149,724,507 | 149,049,197 | |||||||||
Free Cash Flow
Free Cash Flow is intended to provide a measure of our ability to generate cash in excess of capital investments. It provides management with a view of cash flows which can be used to finance operational and strategic investments.
Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, including purchases of equipment.
A reconciliation of GAAP net cash flows provided by operating activities to Free Cash Flow appears in the table below (in thousands):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net cash flows provided by operating activities | $ | 24,956 | $ | 18,782 | 74,003 | 66,198 | |||||||||
| Capital expenditures, including purchases of equipment | (285 | ) | (263 | ) | (1,033 | ) | (1,683 | ) | |||||||
| Free Cash Flow | $ | 24,671 | $ | 18,519 | $ | 72,970 | $ | 64,515 | |||||||
Other Information
Net Sales by Product Category by Quarter
Below is a summary of net sales by product category (in thousands):
| 2025 | 2024 | ||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | ||||||||||||||||
| Wound | $ | 56,073 | $ | 64,476 | $ | 77,098 | $ | 78,679 | $ | 57,049 | $ | 57,547 | $ | 55,052 | $ | 61,357 | |||||||
| Surgical | 32,132 | 34,129 | 36,627 | 39,416 | 27,660 | 29,660 | 29,005 | 31,550 | |||||||||||||||
| Net sales | $ | 88,205 | $ | 98,605 | $ | 113,725 | $ | 118,095 | $ | 84,709 | $ | 87,207 | $ | 84,057 | $ | 92,907 | |||||||
Selling, General and Administrative
Below is the breakout of selling, general and administrative expense by selling and marketing and general and administrative (in thousands):
| 2025 | 2024 | ||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | ||||||||||||||||
| Selling and marketing | $ | 46,861 | $ | 47,867 | $ | 53,720 | $ | 61,233 | $ | 44,477 | $ | 41,725 | $ | 41,721 | $ | 47,638 | |||||||
| General and administrative | 13,108 | 16,284 | 15,281 | 11,840 | 10,652 | 13,676 | 11,795 | 13,403 | |||||||||||||||
| Selling, general and administrative | $ | 59,969 | $ | 64,151 | $ | 69,001 | $ | 73,073 | $ | 55,129 | $ | 55,401 | $ | 53,516 | $ | 61,041 | |||||||
